Share prices of Cipla and Sanofi India were trading higher in the early trade on March 27 after the companies entered into distribution agreement for Sanofi's central nervous system product range.

Drugmaker Cipla expects to put the “slow seasonal growth” of its ‘One India’ business in the last quarter behind it, even as it looks to resolve supply issues involving its generic ...

Cipla's total revenue for the quarter rose 5.6%, slightly below analysts' expectations of a 5.8% growth. ($1 = 84.0480 Indian ...

Meanwhile, sales in India experienced a 4.7% year-over-year growth, which was tempered by slower growth in acute therapy. Cipla has reaffirmed its forecast for the India business to surpass the ...

Similar deaths were reported in Uzbekistan, where 18 children had died till 2022 allegedly after consuming an Indian manufactured cough syrup, according to the country's health ministry. In India ...